Cipla Q1 FY27 earnings call: Revenue & Margins
Q1 FY27 earnings call: what management said on revenue, margins and capex.
- Revenue
- ₹7,119Cr
- +2.3% YoY
- +8.8% QoQ
- Net profit
- ₹786Cr
- −39.2% YoY
- +44.8% QoQ
- Margin
- 17%
- −9 pp YoY
- +2 pp QoQ
Guidance rank: #60 of 87 in Pharmaceuticals & Biotechnology
See the sector's top 10 — free with your mobile number.
What the Q1 FY27 call signalled
2 of 3 strong
The short version
Cipla targets meaningful growth leading to a $1 billion exit in North America, driven by large new product launches expected to ramp up through the year. Cipla's current EBITDA margin (~16.7%) is below steady-state due to operating expenses from new product launches and temporary war impacts (1-2% margin hit). - The company expects sharp margin improvement as new products start generating revenue and facilities become better utilized. - Cost optimization and productivity initiatives are underway to support margin growth. - EBITDA margin guidance is 18.5% to 20% for FY27, predicated on successful new launches. - Cipla refrains from providing specific long-term margin targets but aims for gradual sequential margin improvement. - New product launches in the U.S.
From Cipla Ltd's Q1 FY27 earnings-call transcript · updated 16 Oct 2026.
Revenue & Sales Performance
- Cipla targets meaningful growth leading to a $1 billion exit in North America, driven by large new product launches expected to ramp up through the year.
- New product launches in the U.S. (including 3 respiratory assets and a key peptide opportunity) are expected to contribute significantly to revenue, with supply scaling towards the end of the financial year.
- India business is focused on sustaining growth momentum with a double-digit growth trajectory, especially in chronic therapies like respiratory, diabetes, cardiology, urology, and dermatology. Chronic portfolio in India is targeted to increase from 60% now to possibly around 65% in 2-3 years.
2 more points from Cipla Ltd's call on revenue
Create a free account to keep reading this call
Profitability & Margins
See what Cipla Ltd said on profitability & margins — free account, 30 seconds.
Capital Expenditure Plans
- Cipla has increased capex focused on organic growth.
- Significant investments are directed toward R&D, especially biosimilars.
- The company is actively pursuing differentiated portfolios through acquisitions or in-licensing, which may require upfront payments.
2 more points from Cipla Ltd's call on capex
Create a free account to keep reading this call
Top-ranked in Pharmaceuticals & Biotechnology
Ranked on what management guided this quarter
Rank buckets describe management commentary on revenue and margin. Not investment advice, and not a forecast of returns.
Fundraising & Capital Structure
See what Cipla Ltd said on fundraising & capital structure — free account, 30 seconds.
Order Book & Pipeline
2 more points from Cipla Ltd's call on order book
Create a free account to keep reading this call
Cipla Ltd — Quarterly revenue & net profit
Cipla Ltd Q1 FY27 results — key figures
| ₹ Cr | Q1 FY27 | Q1 FY26 | YoY | Q4 FY26 | QoQ |
|---|---|---|---|---|---|
| Revenue | 7,119 | 6,957 | +2.3% | 6,541 | +8.8% |
| Operating profit (EBITDA) | 1,192 | 1,778 | -33% | 955 | +24.8% |
| Operating margin | 17% | 26% | -9 pp | 15% | +2 pp |
| Profit before tax | 1,082 | 1,770 | -38.9% | 707 | +53% |
| Net profit (PAT) | 786 | 1,292 | -39.2% | 543 | +44.8% |
| EPS (₹) | 9.77 | 16.06 | -39.2% | 6.87 | +42.2% |
Source: reported quarterly figures (Screener), ₹ crore.
Reported quarterly figures (₹ Cr). Latest (Q2 FY27): revenue ₹7.4K Cr, net profit ₹852 Cr. Revenue and profit are scaled separately — hover a quarter for exact figures.
Full financials →Continue your research
What Cipla's management said in earlier quarters
Others in Pharmaceuticals & Biotechnology this season
- KRM Ayurveda (Q1 FY27)
Total income for Q1 FY27: ₹3,286.55 Lakhs, +32.4% YoY . Key investor presentation takeaways from KRM Ayurveda Ltd's Q1 FY27 investor presentation — and how it r
- Balaxi Pharma (Q1 FY27)
Q1 FY27 Revenue: ₹80.68 crore, up 14.1% YoY from ₹70.74 crore in Q1 FY26 (Page 20). Key investor presentation takeaways from Balaxi Pharma's Q1 FY27 investor pr
- Sanjivani Paranteral (Q1 FY27)
Q1 FY27 consolidated revenue from operations: ₹238.39 Mn, up 33.8% YoY from ₹178.92 Mn in Q1 FY26 (Page 25). Key investor presentation takeaways from Sanjivani
- Natural Capsules (Q1 FY27)
Revenue from Operations for Q1FY27: ₹48.71 crore . Key investor presentation takeaways from Natural Capsules Ltd's Q1 FY27 investor presentation — and how it ra
Potential multibaggers · Q2 FY27
Potential multibaggers in Pharmaceuticals & Biotechnology
on management's own guidance
- Strong growth2
- Strong growth1
- Strong growth3
Portfolio builder
Build your portfolio
from the top-ranked stocks
- 1. Pick 3–15 stocks
- 2. Choose large, mid or small cap and your sectors
- 3. Get a portfolio built from the rankings
Ranks describe management commentary on revenue and margin from the latest earnings call. Not investment advice.
Arthneeti Pro · Annual
Cipla Ltd and 15K+ more earnings calls,
for less than your morning chai
Every earnings call, ranking and concall Q&A across all four results seasons.
Secure Razorpay payment · instant access
Frequently Asked Questions
What were Cipla Ltd Q1 FY27 results?
Cipla targets meaningful growth leading to a $1 billion exit in North America, driven by large new product launches expected to ramp up through the year. Cipla's current EBITDA margin (~16.7%) is below steady-state due to operating expenses from new product launches and temporary war impacts (1-2% margin hit). - The company expects sharp margin improvement as new products start generating revenue and facilities become better utilized. - Cost optimization and productivity initiatives are underway to support margin growth. - EBITDA margin guidance is 18.5% to 20% for FY27, predicated on successful new launches. - Cipla refrains from providing specific long-term margin targets but aims for gradual sequential margin improvement. - New product launches in the U.S.
What is Cipla Ltd share price analysis?
Cipla Ltd currently shows a below-average growth signal. The stock trades at a P/E of 29.9 with a market cap of ₹107,051 Cr. Investors should review the full earnings analysis for detailed insights.
Is Cipla Ltd planning capital expenditure?
Cipla has increased capex focused on organic growth. - Significant investments are directed toward R&D, especially biosimilars. - The company is actively pursuing differentiated portfolios through acquisitions or in-licensing, which may require upfront payments. - They continue to explore M&A opportunities in the U.S.
Keep Cipla Ltd on your radar — track it to get its next earnings analysis in your feed.
This analysis is AI-generated based on publicly available earnings data and the company's earnings call transcript. This is not investment advice. Please consult a SEBI-registered advisor before making investment decisions.
